---
layout: default
title: Ramucirumab
description: "Ramucirumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 144
evidence_level: L5
indication_count: 10
---

# Ramucirumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ramucirumabï¼šå¾èƒƒç™Œåˆ°å­å®®éŸŒå¸¶è…ºç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ramucirumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Ramucirumab åŸæœ¬ç”¨æ–¼æ²»ç™‚èƒƒç™Œã€éå°ç´°èƒè‚ºç™Œã€å¤§è…¸ç›´è…¸ç™Œå’Œè‚ç´°èƒç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å­å®®éŸŒå¸¶è…ºç™Œ (Uterine Ligament Adenocarcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰åƒ…æœ‰æ¨¡å‹é æ¸¬æ”¯æŒï¼Œç„¡è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | èƒƒç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | uterine ligament adenocarcinomaã€endocervical carcinomaã€adenoid cystic carcinoma of the cervix uteriã€uterine ligament serous adenocarcinomaã€signet ring cell variant cervical mucinous adenocarcinomaã€cervical adenosquamous carcinoma, glassy cell variantã€uterine ligament endometrioid adenocarcinomaã€uterine ligament clear cell adenocarcinomaã€uterine ligament mucinous adenocarcinomaã€intestinal variant cervical mucinous adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.95% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | âœ“ å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 4 å¼µ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. uterine ligament adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
ç›®å‰ç¼ºä¹è©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ã€‚æ ¹æ“šå·²çŸ¥è³‡è¨Šï¼ŒRamucirumab æ˜¯ä¸€ç¨®æŠ—è¡€ç®¡ç”Ÿæˆè—¥ç‰©ï¼Œ
é€šéæŠ‘åˆ¶è¡€ç®¡å…§çš®ç”Ÿé•·å› å­å—é«” (VEGFR) çš„æ´»æ€§ä¾†æ¸›å°‘è…«ç˜¤è¡€ç®¡ç”Ÿæˆã€‚
å…¶æˆåˆ†åœ¨èƒƒç™Œç­‰è…ºç™Œä¸­çš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ï¼Œæ©Ÿè½‰ä¸Šå¯èƒ½é©ç”¨æ–¼å­å®®éŸŒå¸¶è…ºç™Œã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

ç›®å‰ç„¡ç›¸é—œæ–‡ç»ã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. endocervical carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.95%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. adenoid cystic carcinoma of the cervix uteri</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.95%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. uterine ligament serous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. signet ring cell variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. cervical adenosquamous carcinoma, glassy cell variant</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. uterine ligament endometrioid adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. uterine ligament clear cell adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. uterine ligament mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. intestinal variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬000999è™Ÿ | æ¬£éŠ³æ“‡ æ³¨å°„åŠ‘ | æ³¨å°„åŠ‘ | èƒƒç™Œã€éå°ç´°èƒè‚ºç™Œã€å¤§è…¸ç›´è…¸ç™Œã€è‚ç´°èƒç™Œ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | æ¨™é¶è—¥ç‰© |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | ä¸­ç­‰ |
| è‡´åæ€§åˆ†ç´š | ä½è‡³ä¸­åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è‚è…åŠŸèƒ½ |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šèˆ‡ Acetylsalicylic acidã€Deferasiroxã€Ibritumomab tiuxetan ç­‰æœ‰é‡å¤§äº¤äº’ä½œç”¨ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**ç”²ç‹€è…ºæ©Ÿèƒ½ä½ä¸‹ (Hypothyroidism)** ğŸŸ¡ Moderate
- Hypothyroidism has been reported in patients taking ramucirumab.  Therapy with ramucirumab should be administered cautiously to patients with thyroid dysfunction.  Baseline laboratory measurement of thyroid function is recommended and if appropriate,...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- The effect of hepatic impairment on the clearance of ramucirumab was evaluated in patients with mild and moderate hepatic impairment.  No clinically important differences in the clearance of ramucirumab were found between patients with mild or modera...

**é«˜è¡€å£“ (Hypertension)** ğŸŸ¡ Moderate
- Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure.  Therapy with these agents should be administered cautiously in patients with preexisting hypertension.  Blood pressure s...

**Posterior Leukoencephalopathy Syndrome** ğŸŸ¡ Moderate
- Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies.  PRES is a neurological disorder which can present with headache, seizure, l...

**Proteinuria** ğŸŸ¡ Moderate
- The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR).  Therapy with these agents should be administered cautiously in patients with renal dysfunction.  Monitoring...

*å¦æœ‰ 3 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
ç›®å‰åƒ…æœ‰æ¨¡å‹é æ¸¬æ”¯æŒï¼Œç¼ºä¹è‡¨åºŠè©¦é©—å’Œæ–‡ç»è­‰æ“šï¼Œè­‰æ“šç­‰ç´šç‚º L5ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—ä»¥é©—è­‰ç™‚æ•ˆ
- è©³ç´°çš„è—¥ç‰©ä½œç”¨æ©Ÿè½‰è³‡æ–™ï¼ˆMOAï¼‰


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Nebivolol]({{ "/drugs/nebivolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pipemidic Acid]({{ "/drugs/pipemidic_acid/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Griseofulvin]({{ "/drugs/griseofulvin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Inclisiran]({{ "/drugs/inclisiran/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Bevacizumab]({{ "/drugs/bevacizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ramucirumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ramucirumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ramucirumab,
  title = {Ramucirumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ramucirumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
